Wednesday, May 06, 2015 7:25:54 AM
1. Why not announce ahead of time the company is transforming, get people excited and let them in on the plans?? Let them know what has to go and where the future is taking us. They actually could have got people to hold the stock and PPS, maybe even new investors looking for that upside. Instead they blind sided everyone not knowing what was going on. People do not like to not know what is happening when it involves there money. I think I can make the statement that everybody already knew that we where not going to have great 1st quarter. That is not what made the stock drop.
2. Name change? Probably a good reason but why not have mentioned the reason for this? There are a lot of reasons people change the name of there company, some are good and some are bad! We don't know if we are incorporated, partnered, bought, bankrupt or just looking to move on with a new name? I think a lot of people wondered about this.
3. What happened to the Tissue Regeneration Program VSELsTM? Its page is gone off the site? Did we not get a grant to continue this program? Is this temporary or has the trade mark been sold? Who knows I am in the dark!
4. Management. Yes we have new management but I do not think there approach is any different than the last. They need somebody in there that has a good public approach on how to advertise this stock. I did say advertise because your display of the company can make it or break it!
My opinion>>
Why not announced a couple weeks of head of time we are>>>
TRANSFORMING this company which includes a corporate name and brand identity in the coming weeks to emphasize the Company’s therapeutic development focus on immune therapy and its integrated approach to cell therapy. We have big and positive changes we will be announcing along the way! You will see changes to our site, please give them time to be all updated, we will announce when that is done!
People would not have been blind sided. They could have got us excited by some CEO post about what this would included and that our future is going to be positive! Actually no matter what they put out now we have lost a lot of PPS and especially confidence in the company, I feel this could have been avoided. These things are hard to recover from. Not to bring up old crap but just like the first results of NBS10 they waited to long to reply, we all took that hit! The second time you think they would have been ready? Again the PPS dropped no reply for a couple days?? We have not recovered yet! Then yesterday did not help at all, down we go again!
I feel and I know it is true that we have had good results!! Then why is the PPS so low? We have dropped to almost nothing and yes it is a good buying opportunity with out a doubt! You need confidence in a company to buy and hold the PPS.
Last let me say, I believe in NBS, there science, there trails. THEY ARE THE FUTURE OF MEDICNE ! I just wish they would adopt that thought when printing articles or displaying news! I wish they would keep the ball rolling with updates about our products, our future! Little words mean a lot! I wish the CEO would take 10 minutes a week to post on his blog( it does not have to be a lot, little progress reports, anything)
Recent LSTA News
- Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer • GlobeNewswire Inc. • 05/20/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/10/2024 04:15:16 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:13:47 PM
- Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events • GlobeNewswire Inc. • 05/08/2024 12:00:00 PM
- Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma • GlobeNewswire Inc. • 04/23/2024 11:30:00 AM
- Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma • GlobeNewswire Inc. • 04/09/2024 12:30:00 PM
- Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Lisata Therapeutics to Present at BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
- Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Lisata Therapeutics to Present at NobleCon19 Investor Conference • GlobeNewswire Inc. • 11/28/2023 09:05:00 PM
- Lisata Therapeutics Announces Participation in Upcoming Conferences in November • GlobeNewswire Inc. • 11/09/2023 09:05:00 PM
- Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/02/2023 08:05:00 PM
- Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time • GlobeNewswire Inc. • 10/26/2023 12:00:00 PM
- Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide • GlobeNewswire Inc. • 10/24/2023 12:00:00 PM
- Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 10/17/2023 12:00:00 PM
- Lisata Therapeutics Announces Participation in Upcoming Conferences in October • GlobeNewswire Inc. • 09/28/2023 12:00:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM